Related Experiment Video
Updated: Aug 12, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional
Shinsuke Yamashita1,2, Yoshitaka Saito3, Shinya Tamaki4
1Graduate School of Life Science, Hokkaido University, Kita 10 Nishi 8, Kita-ku, Sapporo, Hokkaido 060-0810, Japan.
Background:
Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify the factors associated with this symptom in patients with non-small cell lung cancer (NSCLC).
Methods:
This retrospective multicenter observational study evaluated 170 patients with NSCLC who received DTX between April 2014 and December 2024. The primary endpoint was factors associated with grade ≥ 2 DTX-induced peripheral edema during up to seven cycles. Additionally, we evaluated the factors for all-grade symptoms.
Results:
The incidences of grade ≥ 2 and all-grade DTX-induced peripheral edema were 13.5% and 30.0%. The median cumulative DTX dose at symptom onset was 144 (interquartile range, 60-254) mg/m2 for grade ≥ 2 DTX-induced peripheral edema and 120 (60-210) mg/m2 for all-grade symptoms. The Fine-Gray sub-distribution hazard models revealed that the co-administration of ramucirumab (RAM) was significantly associated with the incidence of DTX-induced peripheral edema (grade ≥ 2: sub-distribution hazard ratio [SDHR], 3.51; 95% confidence interval [CI], 1.34-9.24; P = 0.011) (all-grade: SDHR, 2.17; 95% CI, 1.20-3.92; P = 0.011). The Gray's test demonstrated that the cumulative incidence of DTX-induced peripheral edema was significantly higher in the DTX + RAM group than in the DTX monotherapy group (P = 0.003 and < 0.001 for grade ≥ 2 and all-grade symptoms, respectively).
Conclusions:
We revealed that co-administration of RAM is a risk factor for DTX-induced peripheral edema in patients with NSCLC.